Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cerilliant
Covington
QuintilesIMS
Boehringer Ingelheim
Daiichi Sankyo
UBS
Harvard Business School
Cipla
Medtronic

Generated: October 18, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR IBUPROFEN LYSINE

« Back to Dashboard

Clinical Trials for IBUPROFEN LYSINE

Trial ID Title Status Sponsor Phase Summary
NCT00440804 Safety and Efficacy Study of Ibuprofen l-Lysine Solution in Premature Infants for Treatment of PDA Completed Farmacon Phase 3 The purpose of this study is to determine the safety and effectiveness of ibuprofen l-lysine iv in premature infants in the early treatment of Patent Ductus Arteriosus.
NCT03180879 Ibuprofen Bioavailability Study Active, not recruiting Simbec Research Phase 1 This project is the in-house development of a 200 mg ibuprofen acid orodispersable tablet (ODT; meltlet). It is designed to appeal to consumers who want a dosage form that may be taken without water and can be used 'on the go'. Vanquish has an improved organoleptic profile compared to the currently marketed meltet by the Sponsor. ODTs are also considered as a suitable dosage form for children who may be reluctant to swallow tablets. This product has the potential for application in both adults and children due to the convenience of the format and the ease of administration for both groups. This will be the first pharmacokinetic (PK) assessment of the ibuprofen acid ODT formulation.
NCT03180879 Ibuprofen Bioavailability Study Active, not recruiting Reckitt Benckiser Healthcare (UK) Limited Phase 1 This project is the in-house development of a 200 mg ibuprofen acid orodispersable tablet (ODT; meltlet). It is designed to appeal to consumers who want a dosage form that may be taken without water and can be used 'on the go'. Vanquish has an improved organoleptic profile compared to the currently marketed meltet by the Sponsor. ODTs are also considered as a suitable dosage form for children who may be reluctant to swallow tablets. This product has the potential for application in both adults and children due to the convenience of the format and the ease of administration for both groups. This will be the first pharmacokinetic (PK) assessment of the ibuprofen acid ODT formulation.
NCT03497715 Gamma Scintigraphy Study to Investigate Tablet Disintegration in Healthy Volunteers. Terminated Reckitt Benckiser Healthcare (UK) Limited Phase 1 The study will be an adaptive, 2 part, single dose, 5-way crossover gamma scintigraphy study in healthy subjects, to investigate the rate and site of tablet disintegration of various forms of Ibuprofen.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for IBUPROFEN LYSINE

Condition Name

Condition Name for IBUPROFEN LYSINE
Intervention Trials
Healthy Subjects 1
Healthy 1
Patent Ductus Arteriosus 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for IBUPROFEN LYSINE
Intervention Trials
Ductus Arteriosus, Patent 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for IBUPROFEN LYSINE

Trials by Country

Trials by Country for IBUPROFEN LYSINE
Location Trials
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for IBUPROFEN LYSINE

Clinical Trial Phase

Clinical Trial Phase for IBUPROFEN LYSINE
Clinical Trial Phase Trials
Phase 3 1
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for IBUPROFEN LYSINE
Clinical Trial Phase Trials
Active, not recruiting 1
Completed 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for IBUPROFEN LYSINE

Sponsor Name

Sponsor Name for IBUPROFEN LYSINE
Sponsor Trials
Reckitt Benckiser Healthcare (UK) Limited 2
Simbec Research 1
Farmacon 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for IBUPROFEN LYSINE
Sponsor Trials
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
Mallinckrodt
Accenture
Fish and Richardson
Cantor Fitzgerald
Moodys
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.